Peripherally applied synthetic peptide isoAsp7-Aβ(1-42) triggers cerebral β-amyloidosis

Neurotoxicity Research

Volumn 24, Issue 3, 2013, Pages 370-376

  Kozin, S A ^a,b   Cheglakov, I B ^a   Ovsepyan, A A ^c   Telegin, G B ^c   Tsvetkov, P O ^a   Lisitsa, A V ^b   Makarov, A A ^a  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Amyloid peptide; Alzheimer's disease; Cerebral amyloidosis; Isoaspartate; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ISOASPARTIC ACID; SYNTHETIC PEPTIDE;

AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN DISEASE; BRAIN REGION; CEREBRAL AMYLOIDOSIS; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THALAMUS NUCLEUS; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; ANIMALS; BRAIN; INJECTIONS, INTRAVENOUS; ISOASPARTIC ACID; MALE; MICE; MICE, INBRED C3H; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID;

EID: 84883447761     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-013-9399-y     Document Type: Article

References (44)

1. Archer T, Kostrzewa R, Beninger R, Palomo T (2011) Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions. Neurotox Res 19(2):211-234. doi: 10.1007/s12640-010-9190-2
2. Bachurin S, Shelkovnikova T, Ustyugov A, Peters O, Khritankova I, Afanasieva M, Tarasova T, Alentov I, Buchman V, Ninkina N (2012) Dimebon slows progression of proteinopathy in γ-Synuclein transgenic mice. Neurotox Res 22(1):33-42. doi: 10.1007/s12640-011-9299-y
3. Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ (1993) Evidence for the experimental transmission of cerebral beta-amyloidosis to primates. Int J Exp Pathol 74(5):441-454
4. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19(4):939-945
5. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX, Roth K, Aguzzi A, Staufenbiel M, Walker LC, Jucker M (2009) Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A 106(31):12926-12931. doi: 10.1073/pnas.0903200106
6. Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330(6006):980-982. doi: 10.1126/science.1194516
7. Franklin K, Paxinos G (2008) The mouse brain in stereotaxic coordinates. Academic Press, New York
8. Fukuda H, Shimizu T, Nakajima M, Mori H, Shirasawa T (1999) Synthesis, aggregation, and neurotoxicity of the Alzheimer's Aß1-42 amyloid peptide and its isoaspartyl isomers. Bioorg Med Chem Lett 9(7):953-956. doi: 10.1016/s0960-894x(99)00121-3
9. Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy E, Checler F, Glabe C, Bilker WB, Abel T, Schmeidler J, Ehrlich ME (2010) Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol 68(2):220-230. doi: 10.1002/ana.22052
10. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP (2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24(3):516-524
11. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2):101-112. doi: 10.1038/nrm2101
12. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580):353-356. doi: 10.1126/science.1072994297/5580/353
13. Holtzman DM, Morris JC, Goate AM (2011) Alzheimer's disease: the challenge of the second century. Sci Transl Med 3(77):77sr1. doi: 10.1126/scitranslmed.3002369
14. Hosoda R, Saido TC, Otvos L Jr, Arai T, Mann DM, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. J Neuropathol Exp Neurol 57(11):1089-1095
15. Indeykina MI, Popov IA, Kozin SA, Kononikhin AS, Kharybin ON, Tsvetkov PO, Makarov AA, Nikolaev EN (2011) Capabilities of MS for analytical quantitative determination of the ratio of alpha- and betaAsp7 isoforms of the amyloid-beta peptide in binary mixtures. Anal Chem 83(8):3205-3210. doi: 10.1021/ac103213j
16. Jucker M, Walker LC (2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70(4):532-540. doi: 10.1002/ana.22615
17. Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC (2000) Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. J Neurosci 20(10):3606-3611
18. Kumar S, Rezaei-Ghaleh N, Terwel D, Thal DR, Richard M, Hoch M, Mc Donald JM, Wullner U, Glebov K, Heneka MT, Walsh DM, Zweckstetter M, Walter J (2011) Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO J 30(11):2255-2265
19. Kumar S, Singh S, Hinze D, Josten M, Sahl HG, Siepmann M, Walter J (2012) Phosphorylation of amyloid-beta peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes. J Biol Chem 287(11):8641-8651
20. Kuo Y-M, Emmerling MR, Woods AS, Cotter RJ, Roher AE (1997) Isolation, chemical characterization, and quantitation of Aβ 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun 237(1):188-191. doi: 10.1006/bbrc.1997.7083
21. Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M (2011) Soluble Abeta seeds are potent inducers of cerebral beta-amyloid deposition. J Neurosci 31(41):14488-14495. doi: 10.1523/JNEUROSCI.3088-11.2011
22. Masters CL, Selkoe DJ (2012) Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2(6):a006262. doi: 10.1101/cshperspect.a006262
23. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313(5794):1781-1784. doi: 10.1126/science.1131864
24. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C (2012) De novo induction of amyloid-beta deposition in vivo. Mol Psychiatry 17(12):1347-1353. doi: 10.1038/mp.2011.120
25. Ninkina N, Peters O, Millership S, Salem H, van der Putten H, Buchman VL (2009) γ-Synucleinopathy: neurodegeneration associated with overexpression of the mouse protein. Hum Mol Genet 18(10):1779-1794. doi: 10.1093/hmg/ddp090
26. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Ronicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 485(7400):651-655. doi: 10.1038/nature11060
27. Peters OM, Connor-Robson N, Sokolov VB, Aksinenko AY, Kukharsky MS, Bachurin SO, Ninkina N, Buchman VL (2013a) Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice. J Alzheimers Dis 33(4):1041-1049. doi: 10.3233/JAD-2012-121732
28. Peters OM, Shelkovnikova T, Tarasova T, Springe S, Kukharsky MS, Smith GA, Brooks S, Kozin SA, Kotelevtsev Y, Bachurin SO, Ninkina N, Buchman VL (2013b) Chronic administration of dimebon does not ameliorate amyloid-β pathology in 5xFAD transgenic mice. J Alzheimers Dis. doi: 10.3233/JAD-130071
29. Prusiner SB (2012) A unifying role for prions in neurodegenerative diseases. Science 336(6088):1511-1513. doi: 10.1126/science.1222951
30. Ridley RM, Baker HF, Windle CP, Cummings RM (2006) Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm 113(9):1243-1251. doi: 10.1007/s00702-005-0385-2
31. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zurcher-Neely HA, Heinrikson RL, Ball MJ et al (1993) Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 268(5):3072-3083
32. Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo Y-M, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 5(1):18-29. doi: 10.1016/j.jalz.2008. 10.004
33. Rosen RF, Fritz JJ, Dooyema J, Cintron AF, Hamaguchi T, Lah JJ, LeVine H 3rd, Jucker M, Walker LC (2012) Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats. J Neurochem 120(5):660-666. doi: 10.1111/j.1471-4159.2011.07551.x
34. Shimizu T, Watanabe A, Ogawara M, Mori H, Shirasawa T (2000) Isoaspartate formation and neurodegeneration in Alzheimer's disease. Arch Biochem Biophys 381(2):225-234
35. Shimizu T, Fukuda H, Murayama S, Izumiyama N, Shirasawa T (2002) Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease. J Neurosci Res 70(3):451-461. doi: 10.1002/jnr.10350
36. Shimizu T, Matsuoka Y, Shirasawa T (2005) Biological significance of isoaspartate and its repair system. Biol Pharm Bull 28(9):1590-1596
37. Stöhr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, Prusiner SB, Giles K (2012) Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc Natl Acad Sci 109(27):11025-11030. doi: 10.1073/pnas.1206555109
38. Toropygin IY, Kugaevskaya EV, Mirgorodskaya OA, Elisseeva YE, Kozmin YP, Popov IA, Nikolaev EN, Makarov AA, Kozin SA (2008) The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 22(2):231-239. doi: 10.1002/rcm.3357
39. Tsvetkov PO, Popov IA, Nikolaev EN, Archakov AI, Makarov AA, Kozin SA (2008) Isomerization of the Asp7 residue results in zinc-induced oligomerization of Alzheimer's disease amyloid beta(1-16) peptide. ChemBioChem 9(10):1564-1567. doi: 10.1002/cbic.200700784
40. Tsvetkov FO, Makarov AA, Archakov AI, Kozin SA (2009) Effect of isomerization of aspartate-7 on the binding of copper (II) ion by the β-amyloid peptide. Biophysics 54(2):131-134. doi: 10.1134/s0006350909020018
41. Walker LC, Callahan MJ, Bian F, Durham RA, Roher AE, Lipinski WJ (2002) Exogenous induction of cerebral β-amyloidosis in βAPP-transgenic mice. Peptides 23(7):1241-1247
42. Watts JC, Giles K, Grillo SK, Lemus A, DeArmond SJ, Prusiner SB (2011) Bioluminescence imaging of Aβ deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci 108(6):2528-2533. doi: 10.1073/pnas.1019034108
43. Yardeni T, Eckhaus M, Morris HD, Huizing M, Hoogstraten-Miller S (2011) Retro-orbital injections in mice. Lab Anim (NY) 40(5):155-160. doi: 10.1038/laban0511-155
44. Zirah S, Kozin SA, Mazur AK, Blond A, Cheminant M, Segalas-Milazzo I, Debey P, Rebuffat S (2006) Structural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging. J Biol Chem 281(4):2151-2161. doi: 10.1074/jbc.M504454200